167 related articles for article (PubMed ID: 37078928)
1. Challenges in Recruitment and Retention: Leveraging Health-Related Antecedents and Information Carrier Factors to Improve Patient Participation in Pancreatic Cancer Research-A Review Article.
Coffin TB; Kenner BJ
Pancreas; 2022 Oct; 51(9):1074-1082. PubMed ID: 37078928
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.
Wood LD; Canto MI; Jaffee EM; Simeone DM
Gastroenterology; 2022 Aug; 163(2):386-402.e1. PubMed ID: 35398344
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for early detection of pancreatic cancer - miRNAs as a potential diagnostic and therapeutic tool?
Tarasiuk A; Mackiewicz T; Małecka-Panas E; Fichna J
Cancer Biol Ther; 2021 Jun; 22(5-6):347-356. PubMed ID: 34224317
[TBL] [Abstract][Full Text] [Related]
4. Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope?
Partensky C
Pancreas; 2013 Jul; 42(5):729-39. PubMed ID: 23648843
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?
Mardin WA; Mees ST
Ann Surg Oncol; 2009 Nov; 16(11):3183-9. PubMed ID: 19636633
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
7. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer.
Douglas JE; Liu S; Ma J; Wolff RA; Pant S; Maitra A; Tamm EP; Bhosale P; Katz MHG; Varadhachary GR; Koay EJ
BMC Cancer; 2022 Jan; 22(1):14. PubMed ID: 34980020
[TBL] [Abstract][Full Text] [Related]
8. Early diagnosis of pancreatic cancer: What strategies to avoid a foretold catastrophe.
Tonini V; Zanni M
World J Gastroenterol; 2022 Aug; 28(31):4235-4248. PubMed ID: 36159004
[TBL] [Abstract][Full Text] [Related]
9. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
[TBL] [Abstract][Full Text] [Related]
10. New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma.
Mangge H; Niedrist T; Renner W; Lyer S; Alexiou C; Haybaeck J
Curr Med Chem; 2017; 24(28):3012-3024. PubMed ID: 28494747
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial.
Neuzillet C; Vergnault M; Bonnetain F; Hammel P
Trials; 2015 Oct; 16():454. PubMed ID: 26458923
[TBL] [Abstract][Full Text] [Related]
12. Response assessment in pancreatic ductal adenocarcinoma: role of imaging.
Baliyan V; Kordbacheh H; Parakh A; Kambadakone A
Abdom Radiol (NY); 2018 Feb; 43(2):435-444. PubMed ID: 29243123
[TBL] [Abstract][Full Text] [Related]
13. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
Panchal K; Sahoo RK; Gupta U; Chaurasiya A
Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Sahin IH; Askan G; Hu ZI; O'Reilly EM
Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
[TBL] [Abstract][Full Text] [Related]
15. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer.
Haller SD; Monaco ML; Essani K
Viruses; 2020 Nov; 12(11):. PubMed ID: 33213031
[TBL] [Abstract][Full Text] [Related]
16. Neo-adjuvant therapy for pancreatic cancer: hope for the future.
Borazanci E; Sckolnik S; Amini A
Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):579-589. PubMed ID: 30979348
[TBL] [Abstract][Full Text] [Related]
17. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
Orth M; Metzger P; Gerum S; Mayerle J; Schneider G; Belka C; Schnurr M; Lauber K
Radiat Oncol; 2019 Aug; 14(1):141. PubMed ID: 31395068
[TBL] [Abstract][Full Text] [Related]
19. Artificial intelligence for early detection of pancreatic adenocarcinoma: The future is promising.
Mendoza Ladd A; Diehl DL
World J Gastroenterol; 2021 Apr; 27(13):1283-1295. PubMed ID: 33833482
[TBL] [Abstract][Full Text] [Related]
20. Islets and pancreatic ductal adenocarcinoma - An opportunity for translational research from the 'Bench to the Bedside'.
Barreto SG; Michael MZ; Keating DJ
Pancreatology; 2020 Apr; 20(3):385-390. PubMed ID: 32057682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]